Osteoporosis is a multifactorial disease that is characterised by a reduction in bone mass and its mechanical resistance, and leads to an increased propensity to bone fractures. Now, a study has been published in the Spanish review Enfermedades Infecciosas y Microbiología Clínica [Infectious Diseases and Clinical Microbiology] showing the increase in prevalence of this disorder in HIV-1 infected patients.
The principal investigator of the study, José Manuel Olmos, clarifies to SINC that: “As soon as Highly Active Antiretroviral Therapy was introduced, which we call HAART, this infection was transformed into a chronic disease with an acceptable quality of life in the developed countries”.
There are multiple reasons that explain the propensity to osteoporosis in those patients who have the virus. Some are related to the HIV-1 infection itself, such as the lymphocyte activity, the release of cytokines that stimulate bone absorption, hypogonadism (a disorder where the reproductive organs do not function), Vitamin D deficit, malnutrition or low level of physical activity. Other reasons depend on the treatment patients receive with corticosteroid and antiretroviral medicines.
According to the authors, “for the moment, it does not seem that osteoporotic fractures represent a significant problem. However, as the patient gets older a reduction in their quality of life may occur.
As far as Olmos is concerned, “recognition that osteoporosis is one of the late consequences of HIV-1 infection compels us to give an early diagnosis of this disease in these patients, in order to take the necessary preventive and therapeutic measures.
For this reason the study emphasises the need to take a detailed clinical history from HIV-1 infected people, and this should include the classic risk factors for osteoporosis, paying particular attention to treatment that has been received (corticosteriod medicines, HAART, etc) and the pattern of the disease.
In addition to the routine laboratory tests, the authors maintain that in order to optimise the prognosis of the patients, “a bone densitometry scan must be performed wherever there are data relating to hypogonadism, treatment with steroids for chronic disease or a previous history of fractures caused by osteoporosis”.
There is also a scientific consensus as to the recommended preventive measures to take: physical exercise, sufficient ingestion of calcium and Vitamin D, and elimination of risk factors such as alcohol, tobacco and poor diet.
Pharmacological treatment of patients who are diagnosed with osteoporosis is founded usually on the use of bisphosphonates (except in cases where hypogonadism is detected, when it is appropriate to consider suitable hormonal treatment). Bisphosphonates can be administered intermittently, are well tolerated, do not appear to interact with antiretroviral medicines and have proven their use in the prevention and treatment of osteoporosis. However, Olmos asserts that “there is still insufficient experience about the pharmacological treatment of osteoporosis in HIV-1 patients”
“Despite numerous investigations, results are still awaited from a clinical trial undertaken with a group of seropositive patients treated with Alendronate (Adult AIDS Clinical Trial Group 5163), which, doubtless, will bring new evidence about the possible effectiveness of anti-osteoporotic treatment in these patients” conclude the authors.
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences